BIOMAT Database Logo BIOMAT Database Logo

Analysis of immunoregulatory activity of a choriocarcinoma-derived factor: specific suppression of proliferative process of cell-mediated immune responses including LAK cell generation. 1991

N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Department of Obstetrics and Gynecology, Osaka University Medical School, Japan.

The immunosuppressive activity of a JEG-3 choriocarcinoma-derived factor in human IL-2-dependent T cell responses has been studied, together with its effect on IL-2-independent T cell responses induced by 10 nM TPA. The factor completely suppressed the IL-2-independent proliferative responses of T cells but failed to suppress antigenic expression of activation-associated CD 25 molecules. Further studies examined the effect of the factor on LAK cell generation induced by rIL-2. Recombinant IL-2-induced LAK cell proliferation was observed on Day 4 and Day 5, but not on Day 3. As the factor suppressed the responses of LAK cell proliferation, we tested whether it blocked the generation of Day 3, Day 4 and Day 5 LAK cells. The addition of the factor failed to suppress the generation of Day 3 LAK cells, while it partially suppressed the lytic activity of Day 4 LAK cells and completely suppressed that of Day 5 LAK cells. The data suggest the presence of a heterogeneous pattern for LAK cell generation; one without proliferation, but the other requiring proliferation, to acquire killer activity. Taken together with the evidence that the factor failed to suppress NK activity, the choriocarcinoma-derived factor suppressed only the proliferative events of immunocompetent cells, but inhibited neither their activation nor the differentiation events. This immunosuppressive factor might be involved in the prevention of host-mediated rejection of choriocarcinoma cells or maternal rejection of the fetus.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013491 Suppressor Factors, Immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-J) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. Immunologic Suppressor Factors,Suppressor T-Cell Factors,T-Cell Suppressive Factors,T-Suppressor Factors,Factors, Immunologic Suppressor,Factors, T Suppressor,Suppressor Factor (SF4),T Cell Suppressor Factors,Factors, Suppressor T-Cell,Factors, T-Cell Suppressive,Factors, T-Suppressor,Suppressive Factors, T-Cell,Suppressor Factors, T,Suppressor T Cell Factors,T Cell Suppressive Factors,T Suppressor Factors,T-Cell Factors, Suppressor

Related Publications

N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Specific suppression of cell-mediated immune responses.
March 1969, Transplantation proceedings,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Genetic analysis of immune suppression. I. Gene complementation is required for suppression of antigen-specific proliferative responses by T-cell derived factors.
January 1981, Immunogenetics,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Specific heterologous enhancement of immune responses. IV. Specific generation of a thymus-derived enhancing factor.
December 1972, The Journal of experimental medicine,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Suppressor factor activity in cell-mediated immune responses.
October 1978, Journal of the Reticuloendothelial Society,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Immunoregulatory functions of BCG-elicited alveolar macrophages in cell-mediated immune responses.
January 1988, Regional immunology,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Specific suppression of immune responses.
September 1973, Science (New York, N.Y.),
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Suppression of cell-mediated immune responses by dextran sulphate.
December 1977, Immunology,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Fas-mediated cytotoxicity. An immunoeffector or immunoregulatory pathway in T cell-mediated immune responses?
August 1995, Transplantation,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Modulation of the immunoregulatory functions of alveolar macrophages in cell-mediated immune responses.
January 1990, Regional immunology,
N Matsuzaki, and F Saji, and T Okada, and K Sawai, and T Kameda, and O Tanizawa
Generation of a small cell lung cancer variant resistant to lymphokine-activated killer (LAK) cells: association with resistance to a LAK cell-derived, cytostatic factor.
June 1992, Cancer research,
Copied contents to your clipboard!